Genentech received accelerated approval from the FDA for Avastin in combination with paclitaxel chemotherapy for the first-line treatment of patients with locally recurrent or metastatic breast cancer. The approval is based on Phase III study (E2100) results showing that patients with metastatic breast cancer receiving Avastin with paclitaxel compared to paclitaxel alone, doubled progression-free survival. In Europe Avastin received full approval for the treatment of metastatic breast cancer in ...